UA116772C2 - Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 - Google Patents
Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47Info
- Publication number
- UA116772C2 UA116772C2 UAA201409709A UAA201409709A UA116772C2 UA 116772 C2 UA116772 C2 UA 116772C2 UA A201409709 A UAA201409709 A UA A201409709A UA A201409709 A UAA201409709 A UA A201409709A UA 116772 C2 UA116772 C2 UA 116772C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- relates
- antibodies
- methods
- active fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Винахід стосується виділеного моноклонального антитіла або його імунологічно-активного фрагмента, що зв’язується з CD47, де антитіло або його імунологічно-активний фрагмент не викликає значного рівня гемаглютинації червоних кров’яних тілець після введення. Винахід також стосується фармацевтичної композиції , яка містить дане антитіло, для застосування в полегшенні симптомів раку.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261595216P | 2012-02-06 | 2012-02-06 | |
US201261659752P | 2012-06-14 | 2012-06-14 | |
PCT/US2013/024995 WO2013119714A1 (en) | 2012-02-06 | 2013-02-06 | Cd47 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
UA116772C2 true UA116772C2 (uk) | 2018-05-10 |
Family
ID=48947976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201409709A UA116772C2 (uk) | 2012-02-06 | 2013-06-02 | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 |
Country Status (35)
Country | Link |
---|---|
US (4) | US9045541B2 (uk) |
EP (2) | EP3578569A1 (uk) |
JP (1) | JP6273212B2 (uk) |
KR (2) | KR102338833B1 (uk) |
CN (2) | CN104271757B (uk) |
AU (1) | AU2013217114B2 (uk) |
BR (1) | BR112014019331A2 (uk) |
CA (1) | CA2863834A1 (uk) |
CL (1) | CL2014002086A1 (uk) |
CO (1) | CO7111273A2 (uk) |
CR (1) | CR20140406A (uk) |
CY (1) | CY1121911T1 (uk) |
DK (1) | DK2812443T3 (uk) |
EA (1) | EA034778B1 (uk) |
EC (1) | ECSP14016994A (uk) |
ES (1) | ES2743203T3 (uk) |
HK (1) | HK1205195A1 (uk) |
HR (1) | HRP20191500T1 (uk) |
HU (1) | HUE13746964T2 (uk) |
IL (1) | IL233934B (uk) |
LT (1) | LT2812443T (uk) |
ME (1) | ME03512B (uk) |
MX (1) | MX360772B (uk) |
MY (1) | MY169341A (uk) |
NZ (1) | NZ628314A (uk) |
PE (1) | PE20141908A1 (uk) |
PH (1) | PH12014501758B1 (uk) |
PL (1) | PL2812443T3 (uk) |
PT (1) | PT2812443T (uk) |
RS (1) | RS59159B1 (uk) |
SG (2) | SG10201700160RA (uk) |
SI (1) | SI2812443T1 (uk) |
UA (1) | UA116772C2 (uk) |
WO (1) | WO2013119714A1 (uk) |
ZA (1) | ZA201405864B (uk) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE065432T2 (hu) | 2009-05-15 | 2024-05-28 | Univ Health Network | Készítmények és eljárások a Sirp alfa-CD47 kölcsönhatást célzó hematológiai rákok kezelésére |
ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
MX360772B (es) | 2012-02-06 | 2018-11-15 | Inhibrx Inc | Anticuerpos cd47 y metodos de uso de los mismos. |
US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
CA2892585C (en) | 2012-12-03 | 2022-07-05 | Novimmune S.A. | Anti-cd47 antibodies and methods of use thereof |
BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
CN110066341B (zh) | 2012-12-17 | 2023-01-31 | Pf阿根图姆知识产权控股有限责任公司 | 蛋白、缀合物、药物组合物、DNA构建体、宿主细胞及制备人SIRPα融合蛋白的方法 |
EA036963B1 (ru) * | 2013-02-06 | 2021-01-20 | Инхибркс, Инк. | Применение эпитопа cd47 для получения антитела к cd47 |
EP3536709A1 (en) * | 2013-03-15 | 2019-09-11 | The Board of Trustees of The Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
EP3828203B1 (en) * | 2013-12-17 | 2024-04-24 | MHS Care - Innovation LLC | Compositions and methods for treating fatty tissue buildup |
ES2728668T3 (es) * | 2014-01-08 | 2019-10-28 | Univ Leland Stanford Junior | Terapia dirigida para el cáncer de pulmón de células pequeñas |
MX2017006485A (es) | 2014-11-18 | 2018-03-23 | Janssen Pharmaceutica Nv | Anticuerpos anti-cd47, metodos y usos. |
EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
ES2901501T3 (es) | 2015-01-21 | 2022-03-22 | Univ Leland Stanford Junior | Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas |
MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
WO2016141328A2 (en) * | 2015-03-04 | 2016-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd47 |
CN104804093A (zh) * | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
AU2016324316B2 (en) | 2015-09-18 | 2023-02-09 | Arch Oncology, Inc. | Therapeutic CD47 antibodies |
JP2018535692A (ja) * | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターErasmus University Medical Center | 抗cd47抗体及び使用方法 |
ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
CN115350276A (zh) | 2016-04-15 | 2022-11-18 | 小利兰·斯坦福大学托管委员会 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
AR112048A1 (es) * | 2016-05-09 | 2019-09-18 | Celgene Corp | Anticuerpos cd47 y métodos de uso de los mismos |
CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
WO2018009499A1 (en) * | 2016-07-06 | 2018-01-11 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd47併用療法 |
CN107955071B (zh) * | 2016-10-18 | 2021-03-26 | 上海赛远生物科技有限公司 | 人源抗人cd47抗体及其编码基因与应用 |
KR20220104298A (ko) * | 2016-10-20 | 2022-07-26 | 아이-맵 바이오파마 유에스 리미티드 | 새로운 cd47 단일클론 항체 및 그 용도 |
EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
WO2018081897A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
WO2018095428A1 (zh) * | 2016-11-28 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | Cd47抗体、其抗原结合片段及其医药用途 |
KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
WO2018175790A1 (en) * | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
NZ758119A (en) | 2017-04-14 | 2024-03-22 | Tallac Therapeutics Inc | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
CN109096395B (zh) * | 2017-06-20 | 2022-06-24 | 华兰生物工程股份有限公司 | 阻断型cd47纳米抗体及其用途 |
DK3658141T3 (da) | 2017-07-24 | 2023-02-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Behandling af patologiske tilstande ved direkte og indirekte målretning af Sirpalpha-CD47-interaktion |
NZ761568A (en) * | 2017-08-02 | 2022-11-25 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
JP7256580B2 (ja) | 2017-08-18 | 2023-04-12 | ウルトラヒューマン フォー リミティド | 結合剤 |
CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
EP3704157A1 (en) | 2017-11-01 | 2020-09-09 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
EP3541941A4 (en) * | 2017-11-10 | 2019-12-25 | I-Mab Biopharma US Limited | FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES |
EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
EP3743108A4 (en) * | 2018-01-24 | 2022-01-26 | Nanjing Legend Biotech Co., Ltd. | ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RBC AGGLUTINATION |
CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
CN110526972A (zh) * | 2018-05-25 | 2019-12-03 | 江苏恒瑞医药股份有限公司 | 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途 |
CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技(成都)有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
CN112566662A (zh) * | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
CN110615841B (zh) * | 2018-06-20 | 2022-01-04 | 瑞阳(苏州)生物科技有限公司 | 抗人cd47单克隆抗体及其应用 |
EP3813884A4 (en) * | 2018-06-29 | 2022-03-23 | North Carolina State University | IN SITU SPRAYED BIORESPONSIVE IMMUNOTHERAPEUTIC GEL FOR POSTOPERATIVE TREATMENT |
JP2021529219A (ja) * | 2018-07-05 | 2021-10-28 | トリカン・バイオテクノロジー・カンパニー・リミテッドTrican Biotechnology Co., Ltd | ヒト抗cd47抗体およびその使用 |
CN112601762B (zh) | 2018-08-31 | 2023-04-04 | 南京圣和药业股份有限公司 | 抗cd47抗体及其应用 |
SG11202104301SA (en) * | 2018-10-31 | 2021-05-28 | I Mab Biopharma Us Ltd | Novel cd47 antibodies and methods of using same |
WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
WO2020114399A1 (zh) * | 2018-12-03 | 2020-06-11 | 上海开拓者生物医药有限公司 | Cd47抗体及其制备方法和应用 |
TW202104260A (zh) * | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
CN110066336B (zh) * | 2019-05-12 | 2021-11-09 | 杭州科兴生物科技有限公司 | 抗cd47单克隆抗体、片段及其医药用途 |
JP2022535286A (ja) | 2019-06-07 | 2022-08-05 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための方法及び試薬 |
CN113993899B (zh) * | 2019-06-19 | 2024-03-29 | 乐普生物科技股份有限公司 | 抗cd47抗体及其应用 |
US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
CN110256565B (zh) * | 2019-08-02 | 2021-03-23 | 天津大学 | 抗cd47纳米抗体突变体及其应用 |
GB202409022D0 (en) | 2019-09-03 | 2024-08-07 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
US20230136228A1 (en) | 2019-09-18 | 2023-05-04 | Lamkap Bio Alpha AG | Bispecific antibodies against ceacam5 and cd3 |
AU2020353182A1 (en) * | 2019-09-27 | 2022-04-14 | Beijing Starmab Biomed Technology Ltd | Monospecific and multi-specific antibodies |
CA3208912A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
KR20220103959A (ko) * | 2019-10-25 | 2022-07-25 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-cd47 항체 및 그 용도 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US20230090014A1 (en) | 2020-02-28 | 2023-03-23 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1 antibody and applications thereof |
KR20220162130A (ko) | 2020-02-28 | 2022-12-07 | 탈락 테라퓨틱스, 인크. | 트랜스글루타미나제-매개된 접합 |
CN114057876A (zh) * | 2020-07-31 | 2022-02-18 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
WO2022076987A1 (en) | 2020-10-07 | 2022-04-14 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
GB2617474A (en) | 2020-11-04 | 2023-10-11 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
KR20220080375A (ko) | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023277281A1 (ko) | 2021-06-30 | 2023-01-05 | (주)이노베이션바이오 | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 |
KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
CN118221812A (zh) * | 2022-12-14 | 2024-06-21 | 上海迈石生物技术有限公司 | 一种靶向cd47的单克隆抗体及其应用 |
US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
DE69032742T2 (de) | 1989-08-09 | 1999-06-17 | Rhomed, Inc., Albuquerque, N.Mex. | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
WO1994025588A2 (en) | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
ATE196313T1 (de) | 1993-06-04 | 2000-09-15 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0843961B1 (en) | 1995-08-29 | 2007-01-24 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
DE69839492D1 (de) * | 1997-09-11 | 2008-06-26 | Chugai Pharmaceutical Co Ltd | Monoklonale antikörper zur apoptosis-induzierung |
EP1167388A4 (en) | 1999-03-10 | 2002-05-29 | Chugai Pharmaceutical Co Ltd | APOPTOSE INDUCING SINGLE STRING FV |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
KR100454414B1 (ko) | 2001-06-25 | 2004-10-26 | 주식회사 진생사이언스 | 산소를 이용한 개량 홍삼의 제조 방법 |
US20040091486A1 (en) | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
EP1530418A4 (en) | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | METHODS OF IDENTIFYING AND ISOLATING STEM CELLS AND CANCER STEM CELLS |
US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
US20100215640A1 (en) | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
EP1693385A4 (en) * | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | ANTI-CD47 ANTIBODIES HUMANIZED |
CA2546465A1 (en) | 2003-12-05 | 2005-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
KR101223373B1 (ko) * | 2003-12-25 | 2013-01-16 | 교와 핫꼬 기린 가부시키가이샤 | 항 cd40 항체의 변이체 |
AU2005214988A1 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
DE602005020137D1 (de) | 2004-05-07 | 2010-05-06 | Univ North Carolina | Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i |
US8187595B2 (en) | 2004-05-07 | 2012-05-29 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I |
US7728880B2 (en) | 2004-06-25 | 2010-06-01 | Qualcomm Incorporated | Automatic white balance method and apparatus |
ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
JP2009537145A (ja) * | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのcd47と関連した組成物および方法 |
PL2178916T3 (pl) * | 2007-07-31 | 2015-08-31 | Regeneron Pharma | Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania |
KR101710472B1 (ko) | 2007-11-30 | 2017-02-27 | 글락소 그룹 리미티드 | 항원-결합 작제물 |
CA3054220C (en) | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manilpulating phagocytosis mediated by cd47 |
JP2011518313A (ja) | 2008-01-15 | 2011-06-23 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 急性骨髄性白血病幹細胞のマーカー |
KR100962704B1 (ko) | 2008-07-02 | 2010-06-11 | 유상규 | 일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법 |
MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
EP3130674B1 (en) * | 2008-11-03 | 2020-07-08 | ADC Therapeutics SA | Antibodies that specifically block the biological activity of a tumor antigen |
CA3057650A1 (en) | 2009-09-15 | 2011-03-24 | Irving L. Weissman | Synergistic anti-cd47 therapy for hematologic cancers |
WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
US20120283124A1 (en) | 2009-11-10 | 2012-11-08 | Park Christopher Y | Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes |
LT3789038T (lt) | 2010-05-14 | 2022-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47 |
US20130281304A1 (en) | 2010-08-13 | 2013-10-24 | Andrew P. Feinberg | Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors |
US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
MX360772B (es) * | 2012-02-06 | 2018-11-15 | Inhibrx Inc | Anticuerpos cd47 y metodos de uso de los mismos. |
US9073996B2 (en) | 2012-08-31 | 2015-07-07 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1) |
EA036963B1 (ru) | 2013-02-06 | 2021-01-20 | Инхибркс, Инк. | Применение эпитопа cd47 для получения антитела к cd47 |
US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-02-06 MX MX2014009427A patent/MX360772B/es active IP Right Grant
- 2013-02-06 BR BR112014019331A patent/BR112014019331A2/pt not_active Application Discontinuation
- 2013-02-06 SI SI201331564T patent/SI2812443T1/sl unknown
- 2013-02-06 CN CN201380017900.0A patent/CN104271757B/zh active Active
- 2013-02-06 AU AU2013217114A patent/AU2013217114B2/en active Active
- 2013-02-06 HU HUE13746964A patent/HUE13746964T2/hu unknown
- 2013-02-06 US US13/761,087 patent/US9045541B2/en active Active
- 2013-02-06 ES ES13746964T patent/ES2743203T3/es active Active
- 2013-02-06 CN CN202010418862.1A patent/CN111533804A/zh active Pending
- 2013-02-06 WO PCT/US2013/024995 patent/WO2013119714A1/en active Application Filing
- 2013-02-06 JP JP2014556634A patent/JP6273212B2/ja active Active
- 2013-02-06 DK DK13746964.9T patent/DK2812443T3/da active
- 2013-02-06 PE PE2014001225A patent/PE20141908A1/es not_active Application Discontinuation
- 2013-02-06 EP EP19173042.3A patent/EP3578569A1/en active Pending
- 2013-02-06 SG SG10201700160RA patent/SG10201700160RA/en unknown
- 2013-02-06 ME MEP-2019-232A patent/ME03512B/me unknown
- 2013-02-06 SG SG11201404638SA patent/SG11201404638SA/en unknown
- 2013-02-06 EP EP13746964.9A patent/EP2812443B1/en active Active
- 2013-02-06 RS RSP20191071 patent/RS59159B1/sr unknown
- 2013-02-06 PL PL13746964T patent/PL2812443T3/pl unknown
- 2013-02-06 KR KR1020207009892A patent/KR102338833B1/ko active IP Right Grant
- 2013-02-06 MY MYPI2014002294A patent/MY169341A/en unknown
- 2013-02-06 LT LTEP13746964.9T patent/LT2812443T/lt unknown
- 2013-02-06 CA CA2863834A patent/CA2863834A1/en active Pending
- 2013-02-06 PT PT13746964T patent/PT2812443T/pt unknown
- 2013-02-06 NZ NZ628314A patent/NZ628314A/en unknown
- 2013-02-06 EA EA201400875A patent/EA034778B1/ru not_active IP Right Cessation
- 2013-02-06 KR KR1020147025286A patent/KR102100388B1/ko active IP Right Grant
- 2013-06-02 UA UAA201409709A patent/UA116772C2/uk unknown
-
2014
- 2014-08-04 IL IL233934A patent/IL233934B/en unknown
- 2014-08-05 PH PH12014501758A patent/PH12014501758B1/en unknown
- 2014-08-06 CL CL2014002086A patent/CL2014002086A1/es unknown
- 2014-08-06 CO CO14171778A patent/CO7111273A2/es unknown
- 2014-08-11 ZA ZA2014/05864A patent/ZA201405864B/en unknown
- 2014-09-01 CR CR20140406A patent/CR20140406A/es unknown
- 2014-09-02 EC ECIEPI201416994A patent/ECSP14016994A/es unknown
-
2015
- 2015-04-29 US US14/700,105 patent/US9663575B2/en active Active
- 2015-06-17 HK HK15105746.9A patent/HK1205195A1/xx unknown
- 2015-08-31 US US14/841,619 patent/US20160251435A1/en not_active Abandoned
-
2019
- 2019-08-19 CY CY20191100884T patent/CY1121911T1/el unknown
- 2019-08-20 HR HRP20191500 patent/HRP20191500T1/hr unknown
-
2021
- 2021-02-08 US US17/170,854 patent/US20210317205A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
CY1123435T1 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
BR112014024494A2 (pt) | dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
PE20170779A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos | |
UY35044A (es) | ANTICUERPOS ANTI-dDr1 | |
PE20160528A1 (es) | Anticuerpos | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
UA117657C2 (uk) | Антитіло до трансглютамінази 2 (tg2) | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
EA201992513A1 (ru) | Способ лечения рака груди | |
ECSP13012481A (es) | Composiciones de anticuerpo anti-vegfr-3 |